AA

Apersys Ag

www.apersys.com link_icon

Apersys AG Company Report



1. Company Overview



Name and Mission


  • Name: Apersys AG

  • Mission: At Apersys, we are on a mission to save more patients in need of an organ. Our perfusion platform technology aims to increase the number of transplantable organs and foster translational research.


Founding Details


  • Founded: The origins of the company trace back to 2015 as the Liver4Life project.

  • Founder: Collaboration between ETH Zurich and the University Hospital Zurich.


Key People


  • CEO: Waldemar Hoffmann

  • Head of Engineering: Sven Leppert

  • Scientific Product Manager: Kendra Wernle

  • Senior Regulatory Affairs Manager: Agata Ishizaki

  • Biomedical Engineer: Sina Baumgartner

  • Product Lead: Andrea Venturato

  • Quality Manager: Jenny Papafotopoulou

  • Electrical Engineer: Alfonso Benot Morell

  • Software Engineer: Sandeep Menta

  • Clinical Affairs Lead: Matthias Pfister, MD

  • Senior Consultant: Dawn Balazs-Metz

  • Commercial Lead Consultant: Chris Stahle

  • Junior Development Engineer: Nora Eirich


Headquarters


  • Location: Apersys AG, c/o ETH Zürich, Weinbergstrasse 35, WEH F, 8092 Zürich, Schweiz.


Number of Employees


  • No information is available.


Revenue


  • No information is available.


Known For


  • Apersys AG is known for developing a unique long-term organ perfusion platform that can preserve and recover livers for transplantation.


2. Products



Product Overview


  • Product Name: Apersys Perfusion System

  • Description: A long-term organ perfusion device capable of preserving human organs ex situ for up to 7 days.


Key Features


  • Transition from emergency to elective procedures.

  • Sufficient time to evaluate and select organs.

  • Physiological organ recovery.

  • Organ defatting and treatment.

  • Potential for additional applications such as gene therapy, immunomodulation, and drug testing.


3. Recent Developments



Notable Developments


  • Breakthrough Device Designation: Received from the FDA in March 2024.

  • ISO 13485 Audit: Successfully completed Stage 1 audit on 02.10.2024.

  • Rebranding: Liver4Life has been rebranded as Apersys AG on 03.09.2024.


New Products


  • Launch of a pharmacological-induced defatting device for the human liver.


New Features


  • Introduction of cutting-edge technology enabling fat removal from human livers.


Partnerships and Collaborations


  • No information is available.




For inquiries and more detailed information, reach out to Apersys AG via their official communication channels.